VIVEX is expanding our Amnion & Wound Care Distribution Network. Interested in becoming a distribution partner? Click here to learn more.
NP PILOT STUDY
24-Month Durability Results
NRS: 64% of participants achieved a substantial clinical benefit (SCB) with >50% improvement in back pain at 24 months (p<0.001).
ODI: 73% of participants achieved a minimal clinically important difference (MCID) of > 30% improvement in ODI from baseline to 24 months (p<0.001).
Functional Improvement: At baseline, 82% of participants reported severe or crippled back impairment compared to 18% at 24 months (p<0.001).
Read the full publication(s) for complete study results, adverse events, and safety-related information.
6-Month: Beall DP, Davis TT, Amirdelfan K, et al. Nucleus Pulposus Allograft Supplementation in Patients with Lumbar Discogenic Pain: Initial 6-month Outcomes from a Prospective Clinical Pilot Study. Pain Physician. 2024;27(8):E865-E871.
12-Month: Beall DP, Davis TT, Amirdelfan K, et al. Supplemental nucleus pulposus allograft in patients with lumbar discogenic pain: results of a prospective feasibility study. BMC Musculoskeletal Disorders. 2025;26(1):437. Published 2025 May 1. doi:10.1186/s12891-025-08701-0
24-Month: Costandi S, Beall DP, Davis TT, et al. Durability of Supplemental Nucleus Pulposus Allograft in Patients with Lumbar Discogenic Pain. Journal of Pain Research. 2025;18:1901-1908. Published 2025 Apr 9. doi:10.2147/JPR.S516571
OPP STUDY
6-Month Outcomes in Medicare Beneficiaries
NRS: Statistically significant 60% reduction in back pain between baseline and 6 months, with 82% of participants achieving MCID of > 30% reduction in pain (p<0.001).
ODI: 6-month improvement in mean ODI scores was 50%, with 68% of participants achieving MCID
of > 30% improvement in function (p<0.001).
Functional Improvement: At baseline, 53% of participants reported severe or crippled back impairment compared to 11% at 6 months (p< 0.001).
Read the full publication for complete study results, adverse events, and safety-related information.
6-Month: Azeem N, Myers TJ, Tate JL, Gilmore CA, Harper AS, Block JE. Supplemental Nucleus Pulposus Allograft in Patients with Lumbar Discogenic Pain: Evaluation of Clinical Outcomes and Quality of Life in Medicare Beneficiaries. Clinical Interventions in Aging. 2025;20:717-726. Published 2025 May 27. doi:10.2147/CIA.S523457
PUBLICATIONS
Defining the Patient with Lumbar Discogenic Pain: Real World Implications for Diagnosis and Effective Clinical Management
Lorio MP, Beall DP, Calodney AK, Lewandrowski KU, Block JE, Mekhail N. Journal of Personalized Medicine. 2023;13(5):821. Published 2023 May 12. doi:10.3390/jpm13050821
Perspective on Intradiscal Therapies for Lumbar Discogenic Pain: State of Science, Knowledge Gaps, and Imperatives for Clinical Adoption
Lorio MP, Tate JL, Myers TJ, Block JE, Beall DP. Journal of Pain Research. 2024;17:1171-1182. Published 2024 Mar 18. doi:10.2147/JPR.S441180
The Role of ISASS in evolving the Spine Code Landscape: Lumbar Discogenic Pain Receives Specific ICD-10-CM Code
Lorio MP, Yuan HA, Beall DP, Block JE, Andersson GBJ. International Journal of Spine Surgery. 2024;18(4):353-354. Published 2024 Sep 12. doi:10.14444/8622
Successful Intradiscal Treatment of Adjacent Segment with VIA Disc NP Allograft in a 65-Year-Old Woman with L4-Sacrum Laminectomy and Posterior Fusion
Myers, T. J. Pain Medicine Case Reports. The American Society of Interventional Pain Physicians., 2022, 6, 229-233.
A Proposed Diagnostic and Treatment Algorithm for the Management of Lumbar Discogenic Pain
Lorio MP, Beall DP, Myers TJ, et al. Journal of Pain Research. 2025;18:3331-3343. Published 2025 Jul 1. doi:10.2147/JPR.S522750
Safety Evaluation of Intradiscal Delivery of Nucleus Pulposus Allograft for Lumbar Discogenic Pain
Langhorst ML, Kendall DR, Umapathy S, Soin A, Lorio MP. International Journal of Spine Surgery. Published online October 28, 2025. doi:10.14444/8808